A rivastigmine patch monitoring checklist should cover one-patch use, stomach symptoms, weight, skin reactions, pulse-related events, and treatment gaps. Caregivers should confirm the patch every day and watch more closely after treatment starts or the dose increases.
A rivastigmine transdermal system delivers medicine through the skin. According to DailyMed from the U.S. National Library of Medicine, it manages symptoms of mild, moderate, or severe Alzheimer's dementia but does not cure the disease.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Make the daily patch check
- Monitor stomach symptoms and weight
- Know when a skin reaction needs review
- Review pulse-related events and bleeding risk
- Handle an interruption safely
Make the daily patch check
Confirm that the patient is wearing exactly one patch. The previous patch must come off before a new one goes on, and each patch should be replaced every 24 hours. The FDA prescribing information reports that multi-patch errors have caused hospitalization and, rarely, death.
Use this daily checklist: Rotate application sites instead of using the same location repeatedly. Wait at least 14 days before returning to a previous spot. A paper calendar or body-location diagram can help multiple caregivers follow the same rotation.
- Find and remove yesterday's patch.
- Confirm that no second patch remains elsewhere on the body.
- Apply one new patch to clean, dry, intact skin.
- Record the date, time, patch strength, and body location.
- Check that the patch remains attached during the day.
Monitor stomach symptoms and weight
Watch especially closely after the first patch or a dose increase. The main symptoms to track are nausea, vomiting, diarrhea, decreased appetite, and weight loss. Prolonged vomiting or diarrhea can lead to serious dehydration, according to the FDA label. Keep a brief daily record: Record weight consistently so the care team can see changes over time.
Patients weighing less than 50 kilograms, about 110 pounds, need particularly close monitoring for excessive nausea, vomiting, and other toxicity. They may require a lower maintenance dose. Contact the prescribing clinician about persistent vomiting or diarrhea, declining appetite, or weight loss. A dated symptom record helps the clinician judge whether the pattern followed a dose change.
- Whether nausea, vomiting, or diarrhea occurred.
- Whether appetite has decreased.
- Any noticeable weight change.
- When symptoms began and whether they are continuing.
Know when a skin reaction needs review
Inspect the application site after removing each patch. Note whether redness stays confined to the patch area or continues to spread, intensify, swell, blister, or develop small raised bumps called papules. A spreading or worsening reaction may indicate allergic contact dermatitis rather than limited irritation.
The same concern applies when the site does not substantially improve within 48 hours after patch removal. The FDA prescribing information says this pattern calls for discontinuation and medical review. Record when the reaction started, where the patch was placed, and how the skin changed after removal. Do not place another patch on damaged or irritated skin while seeking guidance from the prescribing team.
Review pulse-related events and bleeding risk
Track falls, fainting, and a slow pulse. Rivastigmine can slow the heart rate, and combining it with a beta-blocker may increase the chance of fainting. Patients with conduction disease—a problem affecting the heart's electrical signals—require particular caution. Make sure the care team knows about every beta-blocker the patient uses.
Report fainting, a newly slow pulse, or a change in falls rather than waiting for the next routine review. Avoid inventing a pulse cutoff; ask the clinician what reading should trigger a call for that patient. Also tell the clinician about any ulcer history or use of nonsteroidal anti-inflammatory drugs, commonly called NSAIDs. These patients should be monitored for overt or occult gastrointestinal bleeding, meaning visible or hidden bleeding. Rivastigmine trials did not show a significant increase in ulcers or gastrointestinal bleeding compared with placebo, but individual risk factors still matter.
Handle an interruption safely
If treatment stops for more than three days, do not restart the previous patch dose without contacting the clinician. The prescribing information directs restarting titration at 4.6 mg per 24 hours to reduce the risk of severe vomiting.
Record the date of the last patch, its strength, and why treatment stopped. Give those details to the prescribing team before another patch is applied.
